MarketCap
Facebook
X
TelegramQuarterly report 2024-Q2
added 08-07-2024
Alimera Sciences Operating Cash Flow 2011-2026 | ALIM
Annual Operating Cash Flow Alimera Sciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.3 M | -9.98 M | -3.22 M | -2.19 M | -4.15 M | -11.6 M | -12.9 M | -25.1 M | -45.4 M | -24.3 M | -37.8 M | -21.2 M | -20.7 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -2.19 M | -45.4 M | -17.9 M |
Quarterly Operating Cash Flow Alimera Sciences
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | -566 K | - | - | -2.21 M | - | -9.72 M | - | -6.21 M | - | 1.46 M | - | -2.5 M | - | -1.93 M | 218 K | 548 K | - | -4.57 M | -676 K | 284 K | - | -12.2 M | -8.4 M | -5.05 M | - | -11.2 M | -6.99 M | -4.17 M | - | -22.7 M | -14.2 M | -6.74 M | - | -36.5 M | -27.7 M | -14.7 M | - | -15.2 M | -10.2 M | -6.22 M | - | -28.1 M | -19.1 M | -9.78 M | - | -14.5 M | -10.1 M | -5.41 M | - | -16.1 M | -10.6 M | -4.99 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.46 M | -36.5 M | -9.63 M |
Operating Cash Flow of other stocks in the Drug manufacturers industry
| Issuer | Operating Cash Flow | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Evoke Pharma
EVOK
|
-5.46 M | - | - | $ 36.6 M |  USA |
 |
Calliditas Therapeutics AB (publ)
CALT
|
-435 M | - | -0.1 % | $ 2.03 B |  Schweden |
 |
AcelRx Pharmaceuticals
ACRX
|
-11.4 M | - | 7.5 % | $ 6.35 M | USA |
 |
DURECT Corporation
DRRX
|
-19.1 M | - | - | $ 50.1 M | USA |
 |
Adamis Pharmaceuticals Corporation
ADMP
|
-25.9 M | - | 0.86 % | $ 117 M | USA |
 |
Aerie Pharmaceuticals
AERI
|
-99.2 M | - | - | $ 754 M | USA |
 |
Agile Therapeutics
AGRX
|
-9.58 M | - | 10.11 % | $ 58.2 M | USA |
 |
Cumberland Pharmaceuticals
CPIX
|
4.93 M | $ 5.57 | 0.73 % | $ 82.7 M | USA |
 |
Cronos Group
CRON
|
25.9 M | $ 2.71 | 1.31 % | $ 1.04 B |  Canada |
 |
Harrow Health
HROW
|
43.9 M | $ 31.98 | 3.63 % | $ 1.18 B | USA |
 |
Athenex
ATNX
|
-131 M | - | -23.39 % | $ 1.76 M | USA |
 |
Avadel Pharmaceuticals plc
AVDL
|
-46.9 M | - | - | $ 2.06 B |  France |
 |
Catalent
CTLT
|
268 M | - | - | $ 11.5 B | USA |
 |
HEXO Corp.
HEXO
|
-43.1 M | - | 2.45 % | $ 38.1 M | Canada |
 |
Eagle Pharmaceuticals
EGRX
|
50.7 M | - | -39.89 % | $ 27.7 M | USA |
 |
Endo International plc
ENDP
|
435 M | - | - | $ 28.9 M |  Irlanda |
 |
Bausch Health Companies
BHC
|
1.03 B | $ 5.41 | -1.73 % | $ 1.97 B | Canada |
 |
Organogenesis Holdings
ORGO
|
-10.3 M | $ 2.61 | 2.16 % | $ 331 M | USA |
 |
Pacira BioSciences
PCRX
|
189 M | $ 23.16 | 0.7 % | $ 1.07 B | USA |
 |
Canopy Growth Corporation
CGC
|
-166 M | $ 1.05 | 1.94 % | $ 113 M | Canada |
 |
Solid Biosciences
SLDB
|
-156 M | $ 6.42 | -0.77 % | $ 562 M | USA |
 |
Aurora Cannabis
ACB
|
16 M | $ 3.49 | 0.58 % | $ 191 M | Canada |
 |
Sonoma Pharmaceuticals
SNOA
|
-88 K | $ 1.04 | -2.8 % | $ 1.29 M | USA |
 |
Jupiter Wellness
JUPW
|
-6.4 M | - | - | $ 33.6 M | USA |
 |
Lannett Company
LCI
|
-7.12 M | - | 1.15 % | $ 7.11 M | USA |
 |
OrganiGram Holdings
OGI
|
3.87 M | $ 1.11 | 3.74 % | $ 106 M | Canada |
 |
Tilray
TLRY
|
7.91 M | $ 5.32 | -1.66 % | $ 3.29 B | Canada |
 |
Evolus
EOLS
|
-42.3 M | $ 6.53 | -0.91 % | $ 421 M | USA |
 |
Sundial Growers
SNDL
|
-155 M | $ 1.45 | 1.04 % | $ 3.37 M | Canada |
 |
Emergent BioSolutions
EBS
|
-206 M | $ 8.24 | 1.17 % | $ 422 M | USA |
 |
Veru
VERU
|
-30 M | $ 2.15 | -0.92 % | $ 31.5 M | USA |
 |
Neoleukin Therapeutics
NLTX
|
-77.2 M | - | - | $ 193 M | Canada |
 |
cbdMD
YCBD
|
-1.45 M | $ 0.73 | -0.24 % | $ 2.94 M | USA |
 |
Assertio Holdings
ASRT
|
-28.2 M | $ 23.43 | -0.04 % | $ 150 M | USA |
 |
ProPhase Labs
PRPH
|
28.6 M | - | - | $ 5.07 M | USA |
 |
Radius Health
RDUS
|
-22.4 M | - | - | $ 1.42 B | USA |
 |
PetIQ
PETQ
|
61.9 M | - | 1.64 % | $ 400 M | USA |
 |
Relmada Therapeutics
RLMD
|
-45.8 M | $ 7.05 | -1.67 % | $ 278 M | USA |
 |
Recro Pharma
REPH
|
-1 M | - | -4.76 % | $ 65.3 M | USA |
 |
OptiNose
OPTN
|
-20.5 M | - | - | $ 1.08 B | USA |
 |
SCYNEXIS
SCYX
|
-5.28 M | $ 0.67 | 0.34 % | $ 33.5 M | USA |
 |
PLx Pharma
PLXP
|
-32.1 M | - | -27.8 % | $ 2.56 M | USA |
 |
Viatris
VTRS
|
2.32 B | $ 16.32 | -1.65 % | $ 19 B | USA |
 |
Zomedica Corp.
ZOM
|
-17.6 M | - | -0.21 % | $ 98 M | USA |
 |
Zynerba Pharmaceuticals
ZYNE
|
-23 M | - | - | $ 55.5 M | USA |
 |
Rockwell Medical
RMTI
|
-659 K | $ 0.8 | -2.52 % | $ 28.8 M | USA |
 |
Tricida
TCDA
|
-140 M | - | - | $ 3.25 M | USA |
 |
China Pharma Holdings
CPHI
|
148 K | $ 0.73 | -2.98 % | $ 3.13 M |  China |
 |
TherapeuticsMD
TXMD
|
-159 M | $ 2.11 | 1.35 % | $ 24.4 M | USA |